ENHANCING RESPONSE RATES TO CHEMOTHERAPY IN ESOPHAGEAL CANCER WITH INTRATUMORAL ADMINISTRATION OF THE SMALL-MOLECULE SURVIVING INHIBITOR YM155.

Vistar Inc

Investigators